1189757-60-5 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
6-Oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxylic acid is utilized as a key intermediate in the synthesis of pharmaceutical compounds due to its potential biological activity and ability to engage with multiple biological targets. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Cardiovascular Disease Treatment:
In the medical field, 6-Oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxylic acid is used as a potential calcium channel antagonist for the treatment of cardiovascular diseases. Its ability to modulate calcium channels can help in managing conditions such as hypertension and angina by influencing the heart's contraction and relaxation.
Used in Enhancing Biological Activity and Bioavailability:
The presence of the trifluoromethyl group in 6-Oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxylic acid is used to enhance the compound's overall biological activity and bioavailability. This modification can improve the compound's pharmacokinetic properties, making it more effective in reaching target sites within the body and increasing its therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 1189757-60-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,9,7,5 and 7 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1189757-60:
(9*1)+(8*1)+(7*8)+(6*9)+(5*7)+(4*5)+(3*7)+(2*6)+(1*0)=215
215 % 10 = 5
So 1189757-60-5 is a valid CAS Registry Number.
1189757-60-5Relevant academic research and scientific papers
BENZAMIDE DERIVATIVE
-
Paragraph 1457; 1458, (2015/03/16)
The present invention relates to benzamide derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.
SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS
-
Page/Page column 189, (2010/12/26)
The present invention provides a compound of formula (I') or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor
Ando, Makoto,Sato, Nagaaki,Nagase, Tsuyoshi,Nagai, Keita,Ishikawa, Shiho,Takahashi, Hirobumi,Ohtake, Norikazu,Ito, Junko,Hirayama, Mioko,Mitobe, Yuko,Iwaasa, Hisashi,Gomori, Akira,Matsushita, Hiroko,Tadano, Kiyoshi,Fujino, Naoko,Tanaka, Sachiko,Ohe, Tomoyuki,Ishihara, Akane,Kanatani, Akio,Fukami, Takehiro
experimental part, p. 6106 - 6122 (2009/12/24)
A series of 2-pyridone-containing imidazoline derivatives was synthesized and evaluated as neuropeptide Y Y5 receptor antagonists. Optimization of the 2-pyridone structure on the 2-position of the imidazoline ring led to identification of 1-(difluoromethy
